Updates in the use of bcl-2-family small molecule inhibitors for the treatment of relapsed/refractory multiple myeloma

HIGHLIGHTS

• who: Ricardo D. Parrondo and collaborators from the (UNIVERSITY) have published the research: Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma, in the Journal: Cancers 2022, x of 24/05/2021
• what: This study had a phase I portion and a phase II portion. The aim of the phase I portion of the trial was to assess the safety and pharmacokinetics of venetoclax- dexamethasone and the primary objective of the phase II portion of the trial was to further evaluate efficacy in addition to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.